dr well semaglutide GLP-1² Advanced Weight Loss Therapy We're thrilled to announce that

While this pack was designed to ease common digestive side effects of GLP-1 therapy, its also ideal for anyone experiencing bloating, irregularity, or gut discomfort

GIP is increasingly recognized as a "buffer" for metabolic health, enhancing insulin secretion in a glucose-dependent manner while potentially mitigating the nausea often associated with GLP-1 receptor activation

Overall discontinuation rates due to adverse events were low at 5.9% for CagriSema vs 3.5% for placebo

Its worth clarifying that even if a peptide related to this pathway were to receive FDA approval in the future, approval would depend on a specific product, formulation, manufacturing process, indication, and demonstrated safety and efficacy, explains Dr

What the Research Says About GLP-1s and HS While clinical research is still in early stages, several studies support what many of us in the HS community have seen anecdotally: A 2024 study of patients with HS found that semaglutide reduced the frequency of flares and systemic inflammationflaring decreased from once every 8.5 weeks to once every 12 weeks